Published in J Infect Dis on November 20, 2006
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis (2009) 0.87
T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections. Clin Dev Immunol (2010) 0.79
Global epidemiology of tuberculosis. Lancet (2006) 6.70
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 6.46
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet (2002) 3.75
Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol (1999) 1.97
Prime-boost immunisation strategies for tuberculosis. Microbes Infect (2005) 1.66
Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol (1997) 1.64
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun (2001) 1.60
Application of flow cytometry to the study of HIV infection. AIDS (1990) 1.38
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS (2006) 1.30
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis (1996) 1.21
Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol (2005) 1.19
Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells. J Clin Invest (1994) 1.15
New vaccines for the prevention of tuberculosis. Clin Infect Dis (2002) 1.15
Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans R Soc Trop Med Hyg (2004) 1.09
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Tuberculosis. N Engl J Med (2013) 4.75
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother (2003) 3.83
Endothelial function in HIV-infected persons. Clin Infect Dis (2006) 3.80
A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med (2015) 2.88
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis (2004) 2.83
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS (2004) 2.45
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis (2008) 2.29
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis (2011) 2.07
A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol (2009) 2.00
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res (2006) 1.93
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol (2010) 1.79
Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. J Natl Cancer Inst (2003) 1.79
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst (2007) 1.73
Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One (2010) 1.73
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One (2011) 1.71
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst (2004) 1.67
Sample preparation of Gram-positive bacteria for identification by matrix assisted laser desorption/ionization time-of-flight. J Microbiol Methods (2002) 1.56
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2010) 1.48
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine (2006) 1.48
Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health (2007) 1.47
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int J Radiat Oncol Biol Phys (2010) 1.46
Multilocus sequence typing of Campylobacter jejuni isolates from humans, chickens, raw milk, and environmental water in Quebec, Canada. J Clin Microbiol (2008) 1.46
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med (2006) 1.45
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences. Am J Obstet Gynecol (2002) 1.41
Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology (2007) 1.41
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood (2009) 1.40
Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer (2005) 1.40
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 1.37
Reliable identification of mycobacterial species by PCR-restriction enzyme analysis (PRA)-hsp65 in a reference laboratory and elaboration of a sequence-based extended algorithm of PRA-hsp65 patterns. BMC Microbiol (2008) 1.35
Campylobacteriosis, Eastern Townships, Quebec. Emerg Infect Dis (2004) 1.35
A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2012) 1.33
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol (2005) 1.30
Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother (2004) 1.30
Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (2003) 1.28
Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol (2013) 1.27
Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One (2012) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
A controlled trial of methods for managing pain in primary care patients with or without co-occurring psychosocial problems. Ann Fam Med (2006) 1.25
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer (2009) 1.20
Clinical and epidemiological correlates of genotypes within the Mycobacterium avium complex defined by restriction and sequence analysis of hsp65. J Clin Microbiol (2002) 1.15
New vaccines for the prevention of tuberculosis. Clin Infect Dis (2002) 1.15
Integration of a participatory research strategy into a rural health survey. J Gen Intern Med (2003) 1.14
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health (2008) 1.14
SunSafe in the Middle School Years: a community-wide intervention to change early-adolescent sun protection. Pediatrics (2007) 1.13
Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol (2004) 1.12